Reimbursement for high-priced innovative medical devices in a DRG-based hospital care system: the German situation.
The implementation of high-priced innovative medical technologies in a diagnosis-related group-type hospital-care reimbursement system is a challenge. If the extra costs are not reimbursed, there will be no financial incentive for a hospital to use a new technology, except for marketing reasons and research projects. A continuous in-time adaptation of the catalog of reimbursed items is necessary.
Hessel
Franz
F
Alfried Krupp von Bohlen und Halbach Foundation, Institute for Healthcare Management, Faculty of Economics, University of Duisburg-Essen, Campus Essen D-45117 Essen, Germany. franz.hessel@uni-due.de